uniQure reported Q1 2026 financial results and progress on its gene therapy pipeline, notably AMT-130 for Huntington’s disease. The company plans a UK Marketing Authorization Application submission in Q3 2026 after positive MHRA feedback and will discuss new clinical trial designs with the FDA in Q2. Clinical updates for AMT-260 epilepsy and AMT-130 four-year data are expected later in 2026. uniQure holds $586.6 million cash, funding operations into late 2029, supporting ongoing development and regulatory efforts.
Innovative Industrial Properties (IIPR) is currently undervalued, trading at 8 times its 2026 annualized first-quarter net funds from operations (NFFO), compared to peers at 14.37 times. The company offers a high dividend yield of 13.32%, though this...
Occidental Petroleum changed its capital strategy in 2023 from reducing debt to redeeming preferred stock, influenced by fluctuating commodity prices. This shift may continue into 2024, affecting the company's balance sheet and cost of capital. Inves...
Figma has been upgraded to a buy rating following a strong first quarter where it reported 43% year-over-year revenue growth and raised its revenue outlook to over $1.4 billion for the year. The company continues to show robust customer retention nea...
Yanik Guillemette, a Canadian tech entrepreneur, criticizes Ottawa's increasing digital regulations, including a proposed 15% revenue tax on streaming platforms and laws C-11, C-18, and C-22. He argues these measures burden the tech ecosystem, raise ...
Yanik Guillemette, a Montreal-based entrepreneur and investment strategist, criticizes Canada's growing digital regulations, including the CRTC's proposal for streaming platforms to fund Canadian content. He argues these rules increase costs for cons...
